As traditional strategies for cancer treatment, some chemotherapy agents, such as
doxorubicin, oxaliplatin, cyclophosphamide, bortezomib, and paclitaxel exert their anti-tumor …

Glioblastoma multiforme (GBM) is commonly known as the most aggressive primary CNS
tumor in adults. The mean survival of it is 14 to 15 months, following the standard therapy …

Glioblastoma multiforme (GBM) is an aggressive brain cancer showing poor prognosis.
Currently, treatment methods of GBM are limited with adverse outcomes and low survival …

The impressive successes of immune checkpoint blockade antibodies to treat various types
of cancer are limited to minor subsets of patients. Combination therapy strategies, including …

Simple Summary Glioblastoma (GBM) remains the most aggressive brain tumor. Treatment
typically includes surgery and radio/chemotherapy, but in spite of intensive treatment …

Glioblastomas (GBs) are malignant brain tumours with poor prognosis even after aggressive
therapy. Programmed cell death-1 (PD-1) immune checkpoint blockade is a promising …

Simple Summary Glioblastoma (GB) is a malignant brain tumour with no cure, even after the
best treatment. The evaluation of a therapy response is usually based on magnetic …

Glioblastoma is the most frequent aggressive primary brain tumor amongst human adults. Its
standard treatment involves chemotherapy, for which the drug temozolomide is a common …

Glioblastomas (GB) are brain tumours with poor prognosis even after aggressive therapy.
Improvements in both therapeutic and follow‐up strategies are urgently needed. In previous …

Cisplatin has been described as a potent anticancer agent for decades. However, in the
case of glioblastomas, it is only considered a rescue treatment applied after the failure of …